Amgen Oncology is continuing to research and learn more about a study drug, called sotorasib, which is designed specifically for cancers with the KRAS G12C mutation.

Click below to learn more about sotorasib and the KRAS G12C mutation and to find CodeBreaK clinical trials.

Explore CodeBreaK Clinical Trials

If you don’t know whether your cancer has the KRAS G12C mutation, ask your doctor if your cancer has been tested for genetic mutations. You can also contact Amgen for more information.

codebreak-image

A clinical trial for patients with advanced solid tumors that have the KRAS G12C mutation

Status
Active, Not Recruiting

PHASE

Phase 1/2

CONDITION

Advanced solid tumors

STUDY DRUGS

Sotorasib alone or combined with another anti-cancer therapy

codebreak-image

A clinical trial for patients with advanced solid tumors that have the KRAS G12C mutation

Status
Recruiting

PHASE

Phase 1b/2

CONDITION

Advanced solid tumors

STUDY DRUGS

Sotorasib alone or combined with other anti-cancer therapies

codebreak-image

A clinical trial for patients with untreated stage 4 non-small cell lung cancer (NSCLC) whose tumors have the KRAS G12C mutation

Status
Active, Not Recruiting

PHASE

Phase 2

CONDITION

NSCLC

STUDY DRUGS

Sotorasib

codebreak-image

A clinical trial for patients with previously treated metastatic colorectal cancer whose tumors have the KRAS G12C mutation

Status
Recruiting

PHASE

Phase 3

CONDITION

Colorectal cancer

STUDY DRUGS

Sotorasib and panitumumab or other anti-cancer therapies

If you are a physician or another healthcare professional interested in learning more about a CodeBreaK trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.